Loading...
The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia
Antibody–drug conjugates (ADCs) are likely to make a significant contribution in the treatment of acute lymphoblastic leukemia (ALL) by combining the cytotoxicity of chemotherapy with the specificity of monoclonal antibodies. CD22, an endocytic receptor expressed by the majority of B cells, is an ex...
Saved in:
| Published in: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
SAGE Publications
2015
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4556970/ https://ncbi.nlm.nih.gov/pubmed/26425338 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620715596715 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|